| Publication |
Sentence |
Publish Date |
Extraction Date |
Species |
| M Shim, P Cohe. IGFs and human cancer: implications regarding the risk of growth hormone therapy. Hormone research. vol 51 Suppl 3. 2000-04-11. PMID:10592443. |
increased gh levels as seen in acromegaly have been associated with benign prostatic hyperplasia but not with prostate, breast or lung cancers, although colon cancer mortality may be increased. |
2000-04-11 |
2023-08-12 |
human |
| G D Rio, A Velardo, C Mascadri, G Zalteri, G Papi, R Menozzi, A Giustin. Baseline and stimulated catecholamine secretion in normotensive patients with active acromegaly: acute effects of continuous octreotide infusion. European journal of endocrinology. vol 142. issue 2. 2000-03-31. PMID:10664528. |
since few data are available on the catecholamine secretory dynamics in active acromegaly and no evidence exists on catecholamine variations during gh decrease, we studied acromegalic patients before and during octreotide administration. |
2000-03-31 |
2023-08-12 |
Not clear |
| T Laursen, J Møller, S Fisker, J O Jorgensen, J S Christianse. Effects of a 7-day continuous infusion of octreotide on circulating levels of growth factors and binding proteins in growth hormone (GH)-treated GH-deficient patients. Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society. vol 9. issue 6. 2000-02-17. PMID:10629166. |
in patients with acromegaly, clinical improvement has been reported after octreotide (oct) treatment, even in cases of only a moderate suppression of growth hormone (gh) levels. |
2000-02-17 |
2023-08-12 |
rat |
| W Hochban, K Ehlenz, R Conradt, U Brandenbur. Obstructive sleep apnoea in acromegaly: the role of craniofacial changes. The European respiratory journal. vol 14. issue 1. 1999-10-21. PMID:10489851. |
the question addressed by this study was whether growth hormone (gh) induced craniofacial changes might explain persisting osa despite endocrine inactivity in acromegaly. |
1999-10-21 |
2023-08-12 |
Not clear |
| A Grimberg, P Cohe. Growth hormone and prostate cancer: guilty by association? Journal of endocrinological investigation. vol 22. issue 5 Suppl. 1999-10-07. PMID:10442574. |
increased gh levels as seen in acromegaly have been associated with benign prostatic hyperplasia but not with cap. |
1999-10-07 |
2023-08-12 |
human |
| P Dasgupta, A T Singh, R Mukherje. Lipophilization of somatostatin analog RC-160 improves its bioactivity and stability. Pharmaceutical research. vol 16. issue 7. 1999-09-30. PMID:10450929. |
acromegaly is a symptomatically disabling condition, resulting from a growth hormone (gh) secreting pituitary tumor. |
1999-09-30 |
2023-08-12 |
Not clear |
| A Brüel, H Oxlun. The effect of growth hormone on rat myocardial collagen. Growth hormone & IGF research : official journal of the Growth Hormone Research Society and the International IGF Research Society. vol 9. issue 2. 1999-09-23. PMID:10373345. |
growth hormone (gh) can increase cardiac performance, but conditions with gh excess, such as acromegaly, are associated with hypertrophy and fibrosis of the heart. |
1999-09-23 |
2023-08-12 |
rat |
| M Coculesc. Blood-brain barrier for human growth hormone and insulin-like growth factor-I. Journal of pediatric endocrinology & metabolism : JPEM. vol 12. issue 2. 1999-09-14. PMID:10392357. |
high gh levels in csf were reported in acromegaly and also a small increase was reported after chronic administration of hgh in gh-deficiency syndromes. |
1999-09-14 |
2023-08-12 |
human |
| I Halperin, R Casamitjana, L Flores, M Fernandez-Balsells, E Vilardel. The role of IGF binding protein-3 as a parameter of activity in acromegalic patients. European journal of endocrinology. vol 141. issue 2. 1999-09-09. PMID:10427158. |
the production of insulin-like growth factor binding protein-3 (igfbp-3), the main igf-i binding protein, is regulated by gh, and its serum levels are increased in acromegaly. |
1999-09-09 |
2023-08-12 |
Not clear |
| I Halperin, R Casamitjana, L Flores, M Fernandez-Balsells, E Vilardel. The role of IGF binding protein-3 as a parameter of activity in acromegalic patients. European journal of endocrinology. vol 141. issue 2. 1999-09-09. PMID:10427158. |
we investigated its potential value as a parameter of acromegaly activity or remission in comparison with igf-i, taking gh suppression below 2 microg/l after glucose load as the normal standard. |
1999-09-09 |
2023-08-12 |
Not clear |
| D Deplewski, R L Rosenfiel. Growth hormone and insulin-like growth factors have different effects on sebaceous cell growth and differentiation. Endocrinology. vol 140. issue 9. 1999-09-09. PMID:10465280. |
these data are consistent with the concept that increases in gh and igf production contribute in complementary ways to the increase in sebum production during puberty and in acromegaly. |
1999-09-09 |
2023-08-12 |
rat |
| J D Lin, S T Lee, H F Wen. An open, phase III study of lanreotide (Somatuline PR) in the treatment of acromegaly. Endocrine journal. vol 46. issue 1. 1999-09-02. PMID:10426587. |
acromegaly is a disorder caused by excessive secretion of human growth hormone (gh). |
1999-09-02 |
2023-08-12 |
human |
| G A Kaltsas, J J Mukherjee, P J Jenkins, M A Satta, N Islam, J P Monson, G M Besser, A B Grossma. Menstrual irregularity in women with acromegaly. The Journal of clinical endocrinology and metabolism. vol 84. issue 8. 1999-08-19. PMID:10443669. |
however, the independent negative correlation between gh and shbg levels suggests that gh may, directly or indirectly, lead to a fall in shbg, possibly determined by the hyperinsulinemia known to occur in acromegaly. |
1999-08-19 |
2023-08-12 |
Not clear |
| J Khosravi, A Diamandi, J Mistry, R G Krischn. The high molecular weight insulin-like growth factor-binding protein complex: epitope mapping, immunoassay, and preliminary clinical evaluation. The Journal of clinical endocrinology and metabolism. vol 84. issue 8. 1999-08-19. PMID:10443687. |
igfbp-3 complexes measured by elisa-1 and -2 in samples from normal individuals and subjects with gh deficiency, acromegaly, and gh receptor deficiency more tightly correlated with igf-i, igfbp-3, and als than igf-ii. |
1999-08-19 |
2023-08-12 |
human |
| L Ebdrup, S Fisker, H H Sørensen, M B Ranke, H Orsko. Variety in growth hormone determinations due to use of different immunoassays and to the interference of growth hormone-binding protein. Hormone research. vol 51 Suppl 1. 1999-08-17. PMID:10393487. |
there is therefore an urgent requirement and desire within the scientific community, particularly within centres diagnosing and treating gh deficiency and acromegaly, to resolve this problem and to develop a gh assay(s) that measures solely all of the relevant components of circulating gh immunoreactivity. |
1999-08-17 |
2023-08-12 |
Not clear |
| P M Stewart, S E Stewart, P M Clark, M C Sheppar. Clinical and biochemical response following withdrawal of a long-acting, depot injection form of octreotide (Sandostatin-LAR). Clinical endocrinology. vol 50. issue 3. 1999-08-12. PMID:10435053. |
because of an ongoing need to assess a patients response to definitive therapy such as surgery and/or radiotherapy, we aimed to evaluate gh levels and acromegaly symptom scores in patients withdrawing from sandostatin-lar. |
1999-08-12 |
2023-08-12 |
Not clear |
| J Gsponer, N De Tribolet, J P Déruaz, R Janzer, A Uské, R O Mirimanoff, M J Reymond, F Rey, E Temler, R C Gaillard, F Gome. Diagnosis, treatment, and outcome of pituitary tumors and other abnormal intrasellar masses. Retrospective analysis of 353 patients. Medicine. vol 78. issue 4. 1999-08-10. PMID:10424206. |
for screening and follow-up of acromegaly, basal growth hormone (gh) and insulin-like growth factor 1 (igf-1) levels, as well as the paradoxical gh response to trh (present in 2/3 acromegalic patients), could be used as convenient tools, but the most accurate test for diagnosis and prediction of outcome after therapy was gh (lack of) suppression during oral glucose tolerance test. |
1999-08-10 |
2023-08-12 |
Not clear |
| M Matsuno, M Sohmiya, H Yamamoto, Y Kat. An acromegalic patient with pulsatile secretion of growth hormone (GH) coincident with the slow-wave sleep. Endocrine journal. vol 45. issue 5. 1999-08-03. PMID:10395250. |
a 43-year-old woman was admitted to our hospital for further treatment of acromegaly with high plasma gh and igf-i levels after transsphenoidal adenomectomy and subsequent treatment with bromocriptine. |
1999-08-03 |
2023-08-12 |
Not clear |
| M Bondanelli, M R Ambrosio, P Franceschetti, A Margutti, G Trasforini, E C Degli Ubert. Diurnal rhythm of plasma catecholamines in acromegaly. The Journal of clinical endocrinology and metabolism. vol 84. issue 7. 1999-07-26. PMID:10404821. |
in conclusion, our study demonstrates the lack of a clear circadian variation in catecholamine levels and bp in active acromegaly and the return of a significant 24-h rhythm of ne and bp after pituitary surgery, concomitant with the reduction in gh and insulin-like growth factor i serum levels. |
1999-07-26 |
2023-08-12 |
human |
| N Sonino, E Scarpa, A Paoletta, F Fallo, M Boscar. Slow-release lanreotide treatment in acromegaly: effects on quality of life. Psychotherapy and psychosomatics. vol 68. issue 3. 1999-07-06. PMID:10224516. |
it is not known whether medical treatment to lower growth hormone (gh) and insulin-like growth factor (igf)-1 levels may improve the compromised quality of life of patients with acromegaly. |
1999-07-06 |
2023-08-12 |
Not clear |